Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

About this update from Alkermes Plc

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/f78dfd7f7d8b74b1cab3583a0fce05a5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WDRSh22cKw5bGinIukTF2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/f78dfd7f7d8b74b1cab3583a0fce05a5","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/rRWgbyy01oAEv6J7WuyDzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/f78dfd7f7d8b74b1cab3583a0fce05a5","width":1024,"height":512}},"lazy":false},{"type":"text","content":"— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue—","length":171,"tagName":"p","attribs":{}},{"type":"text","content":"— Alixorexton Was Generally Well Tolerated at All Doses Tested —","length":64,"tagName":"p","attribs":{}},{"type":"text","content":"— Phase 3 Brilliance NT1 Study of Alixorexton in Patients With Narcolepsy Type 1 Is Ongoing —","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"DUBLIN, April 16, 2026--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present new data from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at the American Academy of Neurology (AAN) 2026 Annual Meeting, taking place April 18-22, 2026 in Chicago. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH).","length":503,"tagName":"p"},{"type":"text","content":"Vibrance-1, a randomized, placebo-controlled, double-blind phase 2 study conducted in 92 patients with NT1, demonstrated clinically meaningful and statistically significant improvements from baseline compared to placebo in wakefulness, cognition, and fatigue. New data to be presented at AAN augment the detailed positive results from the six-week, randomized double-blind treatment (RDBT) period previously presented at the 2025 World Sleep Congress. The new data demonstrate clinically meaningful improvements from pre-treatment baseline on established...

More updates from Alkermes Plc